News

STAT55mOpinion
A sloppy report on mifepristone is being used to undermine the FDA — and the biotech industry
More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.
Pharmabiz55m
Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation
Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...